Vivos Inc Expands International Operations with India Subsidiary

Author: Hannah Lewis Updated: 09-29-2025 02:00 PM

Vivos Inc. Takes a Bold Step into the Indian Market

Vivos Inc., a key player in innovative treatment solutions, has authorized the formation of a wholly owned subsidiary in India, marking a significant milestone in its expansion strategy. The company has filed for the name Vivos Scientific India LLP, and is currently working towards obtaining the necessary governmental approvals.

Commitment to International Growth

With this move, Vivos Inc. is reaffirming its long-term commitment to the Indian market. The company aims to establish its first international manufacturing center, focusing on its revolutionary products RadioGel and IsoPet. Additionally, this initiative will bolster their efforts in developmental animal testing and expand their capacity to provide commercial treatments for both humans and animals in India.

Significance of the Indian Market

India has been identified as a crucial market due to its potential for growth and innovation in healthcare. Vivos Inc. initiated its first human trials in India recently, which were announced in late 2024. This step is crucial in advancing their approval process with the Drug Controller General of India (DCGI) for additional trials, which are vital for validating their treatments.

Advancements in Clinical Trials

Vivos Inc. is actively pursuing expanded human trials in India, which are supportive of the company's Investigational Device Exemption (IDE) process with the FDA. Feedback from the FDA has shaped the formal protocol for the upcoming phase, which will include full-body PET scans immediately following treatment to ensure the safety profile of RadioGel is rigorously validated.

Leadership Insights

Dr. Michael K. Korenko, CEO of Vivos Inc., emphasized the significance of this decision, stating, "Our expansion into India represents a substantial commitment to leveraging our innovative solutions on a global scale." His steadfast leadership is pivotal for navigating the complexities of international operations and compliance.

Contact Information

For those wanting to learn more, you can reach Dr. Korenko via email at MKorenko@RadioGel.com.

Additionally, you can stay updated on Vivos Inc. by following them on X (Twitter) @VivosIncUSA. To discover more about their cutting-edge products, visit www.VivosInc.com.

Frequently Asked Questions

What led Vivos Inc. to establish a subsidiary in India?

Vivos Inc. sees India as a strategic market for expanding its innovative treatment solutions, including establishing a manufacturing center for RadioGel and IsoPet.

What are the main products of Vivos Inc.?

The primary products include RadioGel and IsoPet, which are designed for both human and animal treatment.

What clinical trials are Vivos Inc. conducting in India?

Vivos Inc. is conducting human trials to validate the safety and efficacy of their products as part of the regulatory approval process.

How is Vivos Inc. planning to enhance its market presence?

By forming a subsidiary in India, Vivos Inc. aims to increase its manufacturing capabilities and expand its treatment services in the region.

Who can I contact for more information about Vivos Inc.?

For inquiries, you can contact Dr. Michael K. Korenko via email at MKorenko@RadioGel.com.

About The Author

Hi there, I'm Hannah Lewis, a writer and financial specialist of 36 years old committed to making money understandable and approachable to everyone. Years of working in the field have given me a thorough grasp of market trends, investment techniques, and economic fundamentals. My objective is to enable people, by means of understandable, useful guidance, to take charge of their financial destiny.

I have written many articles for financial blogs over my career that simplify difficult financial ideas into understandable insights. Being financially literate is a critical ability, and I am passionate about enabling people to confidently manage their financial lives. Regardless of your level of experience, my work will help you at every stage of the investment process. I appreciate being allowed to share in your success and financial expansion.

Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.